ARGX-117

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Delayed Graft Function

Conditions

Delayed Graft Function

Trial Timeline

Feb 17, 2024 → Jul 31, 2026

NCT ID

NCT05907096

About ARGX-117

ARGX-117 is a phase 2 stage product being developed by Argenx for Delayed Graft Function. The current trial status is active. This product is registered under clinical trial identifier NCT05907096. Target conditions include Delayed Graft Function.

What happened to similar drugs?

3 of 4 similar drugs in Delayed Graft Function were approved

Approved (3) Terminated (0) Active (1)

✅azathioprine + sirolimusAstellas PharmaApproved

✅Lemborexant + PlaceboEisaiApproved

✅Desflurane + PropofolBaxterApproved

🔄PegcetacoplanApellis PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05907096	Phase 2	Active	Feb 17, 2024	Jul 31, 2026	Delayed Graft Function
NCT05405361	Phase 2	Active	Jan 18, 2023	Sep 30, 2029	Multifocal Motor Neuropathy (MMN)
NCT05225675	Phase 2	Completed	Mar 31, 2022	Jun 4, 2024	Multifocal Motor Neuropathy

Competing Products

8 competing products in Delayed Graft Function

See all competitors

Product	Company	Stage	Hype Score
azathioprine + sirolimus	Astellas Pharma	Approved	43
Lemborexant + Placebo	Eisai	Approved	50
Belatacept + Everolimus	Bristol Myers Squibb	Phase 1	21
Belatacept + Calcineurin Inhibitor	Bristol Myers Squibb	Phase 2	31
BG9418 (interferon beta-1a)	Biogen	Pre-clinical	23
Desflurane + Propofol	Baxter	Approved	40
Pegcetacoplan	Apellis Pharmaceuticals	Phase 3	41
TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + Diluent	Tonix Pharmaceuticals	Phase 1	11